Publications

2025

Boutros, A., A. M. Taylor, I. Li, N. A. Adegoke, T. Wong, A. H. R. Varey, K. F. Shannon, S. Ch'ng, R. P. M. Saw, T. Pennington, J. Stretch, A. Spillane, A. C. J. van Akkooi, R. A. Scolyer, I. P. da Silva, M. S. Carlino, G. V. Long, S. N. Lo, and A. M. Menzies. "A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma." Eur J Cancer 229, no. 115782 (Oct 2025): 115782. https://dx.doi.org/10.1016/j.ejca.2025.115782.

Long, G. V., N. Nair, D. Marbach, R. A. Scolyer, S. Wilson, D. Cotting, N. Staedler, R. N. Amaria, P. A. Ascierto, A. A. Tarhini, C. Robert, O. Hamid, C. Gaudy-Marqueste, C. Lebbe, E. Munoz-Couselo, A. M. Menzies, C. Pages, G. Curigliano, M. Mandala, N. Jessop, U. Bader, M. Perdicchio, V. Teichgraber, M. Muecke, C. Markert, and C. Blank. "Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: The randomized phase 1b/2 Morpheus-Melanoma trial." Nat Med 0, no. 0 (Sep 2025): 0. https://dx.doi.org/10.1038/s41591-025-03967-2.

Lipson, E. J., S. Dolfi, H. Tang, H. A. Tawbi, F. Medina-Soto, E. Castillo Gutierrez, P. Rutkowski, H. Gogas, E. Murillo, P. A. Ascierto, K. Desai, M. Maio, K. Demers, A. Mazzei, S. Keidel, K. Miller-Moslin, J. X. Yu, F. S. Hodi, D. Schadendorf, G. V. Long, and C. Garnett-Benson. "Unraveling relatlimab-specific biology using biomarker analyses in patients with advanced melanoma in RELATIVITY-047." Clin Cancer Res 31, no. 17 (Sep 2025): 3702–14. https://dx.doi.org/10.1158/1078-0432.CCR-24-2499.

Vergara, I. A., N. G. Maher, A. J. Potter, E. C. Paver, J. W. Conway, S. N. Lo, A. J. Colebatch, G. V. Long, J. S. Wilmott, and R. A. Scolyer. "Discovery and validation of an ancillary genomic test of malignancy for primary melanocytic tumors." Clin Cancer Res 31, no. 17 (Sep 2025): 3742–53. https://dx.doi.org/10.1158/1078-0432.CCR-24-1902.

Braden, J., A. Potter, R. V. Rawson, N. A. Adegoke, S. N. Lo, J. W. Conway, A. M. Menzies, M. S. Carlino, G. Au-Yeung, R. P. M. Saw, A. J. Spillane, K. F. Shannon, T. E. Pennington, S. Ch'ng, D. E. Gyorki, J. R. Howle, J. S. Wilmott, R. A. Scolyer, G. V. Long, and I. P. da Silva. "Longitudinal analysis reveals dynamic changes in histopathologic features in responders to neoadjuvant treatment in a stage III BRAF-mutant melanoma cohort." Mod Pathol 38, no. 8 (Aug 2025): 100776. https://dx.doi.org/10.1016/j.modpat.2025.100776.

Braden, J., J. W. Conway, J. S. Wilmott, R. A. Scolyer, G. V. Long, and I. P. da Silva. "Do BRAF-targeted therapies have a role in the era of immunotherapy?", ESMO Open 10, no. 7 (Jul 2025): 105314. https://dx.doi.org/10.1016/j.esmoop.2025.105314.

Long, G. V., E. Shklovskaya, L. Satgunaseelan, Y. Mao, I. P. da Silva, K. A. Perry, R. J. Diefenbach, T. N. Gide, B. Shivalingam, M. E. Buckland, M. Gonzalez, N. Caixeiro, I. A. Vergara, X. Bai, R. V. Rawson, E. Hsiao, U. Palendira, T. G. Phan, A. M. Menzies, M. S. Carlino, C. Quek, S. M. Grimmond, J. H. A. Vissers, D. Yeo, J. E. J. Rasko, M. Khasraw, B. Neyns, D. A. Reardon, D. M. Ashley, H. Wheeler, M. Back, R. A. Scolyer, J. Drummond, J. S. Wilmott, and H. Rizos. "Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma." Nat Med 31, no. 5 (May 2025): 1557–66. https://dx.doi.org/10.1038/s41591-025-03512-1.

Long, G. V., V. Atkinson, S. N. Lo, A. D. Guminski, S. K. Sandhu, M. P. Brown, M. Gonzalez, G. A. McArthur, and A. M. Menzies. "Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study." Lancet Oncol 26, no. 3 (Mar 2025): 320–30. https://dx.doi.org/10.1016/S1470-2045(24)00735-6.

Newell, F., I. P. da Silva, P. A. Johansson, A. M. Menzies, J. S. Wilmott, V. Addala, M. S. Carlino, H. Rizos, K. Nones, J. J. Edwards, V. Lakis, S. H. Kazakoff, P. Mukhopadhyay, P. M. Ferguson, C. Leonard, L. T. Koufariotis, S. Wood, C. U. Blank, J. F. Thompson, A. J. Spillane, R. P. M. Saw, K. F. Shannon, J. V. Pearson, G. J. Mann, N. K. Hayward, R. A. Scolyer, N. Waddell, and G. V. Long. "Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance." Cancer Cell 43, no. 3 (Mar 2025): 563. https://dx.doi.org/10.1016/j.ccell.2025.01.011.

Reijers, I. L. M., A. M. Menzies, M. Lopez-Yurda, J. M. Versluis, E. A. Rozeman, R. P. M. Saw, W. J. van Houdt, E. Kapiteijn, A. A. M. van der Veldt, K. P. M. Suijkerbuijk, H. Eriksson, G. A. P. Hospers, W. M. C. Klop, A. Torres Acosta, L. Grijpink-Ongering, M. Gonzalez, A. van der Wal, A. Al-Mamgani, A. J. Spillane, R. A. Scolyer, B. A. van de Wiel, A. C. J. van Akkooi, G. V. Long, and C. U. Blank. "Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo." Eur J Cancer 214, no. 115141 (Jan 2025): 115141. https://dx.doi.org/10.1016/j.ejca.2024.115141.

2024

Gide, T. N., Y. Mao, R. A. Scolyer, G. V. Long, and J. S. Wilmott. "Tissue-based profiling techniques to achieve precision medicine in cancer: Opportunities and challenges in melanoma." Clin Cancer Res 30, no. 23 (Dec 2024): 5270–80. https://dx.doi.org/10.1158/1078-0432.CCR-24-1109.

Lim, S. Y., I. P. da Silva, N. A. Adegoke, S. N. Lo, A. M. Menzies, M. S. Carlino, R. A. Scolyer, G. V. Long, J. H. Lee, and H. Rizos. "Size matters: Integrating tumour volume and immune activation signatures predicts immunotherapy response." Mol Cancer 23, no. 1 (Oct 2024): 228. https://dx.doi.org/10.1186/s12943-024-02146-0.

Quek, C., A. Pratapa, X. Bai, G. Al-Eryani, I. P. da Silva, A. Mayer, N. Bartonicek, K. Harvey, N. G. Maher, J. W. Conway, R. J. Kasalo, B. Ben Cheikh, O. Braubach, U. Palendira, R. P. M. Saw, J. R. Stretch, K. F. Shannon, A. M. Menzies, R. A. Scolyer, G. V. Long, A. Swarbrick, and J. S. Wilmott. "Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy." Cell Rep 43, no. 7 (Jul 2024): 114392. https://dx.doi.org/10.1016/j.celrep.2024.114392.

da Silva, I. P., I. Li, S. Ugurel, P. Serra-Bellver, A. Andhale, H. Burnette, F. Aya, J. W. Conway, J. Braden, M. S. Carlino, A. M. Menzies, M. Weichenthal, P. Mohr, R. Gutzmer, A. M. Arance, D. B. Johnson, P. Lorigan, D. Schadendorf, S. N. Lo, and G. V. Long. "Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases." Eur J Cancer 205, no. 1 (Jul 2024): 114101. https://dx.doi.org/10.1016/j.ejca.2024.114101.

Bai, X., G. H. Attrill, T. N. Gide, P. M. Ferguson, K. J. Nahar, P. Shang, I. A. Vergara, U. Palendira, I. P. da Silva, M. S. Carlino, A. M. Menzies, G. V. Long, R. A. Scolyer, J. S. Wilmott, and C. Quek. "Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma." Nat Commun 15, no. 1 (Apr 2024): 3014. https://dx.doi.org/10.1038/s41467-024-47301-9.

Maher, N. G., I. A. Vergara, G. V. Long, and R. A. Scolyer. "Prognostic and predictive biomarkers in melanoma." Pathology 56, no. 2 (Mar 2024): 259–73. https://dx.doi.org/10.1016/j.pathol.2023.11.004.

Rogiers, A., F. Dimitriou, I. Lobon, C. Harvey, I. A. Vergara, I. P. da Silva, S. N. Lo, R. A. Scolyer, M. S. Carlino, A. M. Menzies, and G. V. Long. "Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy." Eur J Cancer 198, no. 113506 (Feb 2024): 113506. https://dx.doi.org/10.1016/j.ejca.2023.113506.

2023

Bai, X., A. Shaheen, C. Grieco, P. D. d'Arienzo, F. Mina, J. A. Czapla, A. R. Lawless, E. Bongiovanni, U. Santaniello, H. Zappi, D. Dulak, A. Williamson, R. Lee, A. Gupta, C. Li, L. Si, M. Ubaldi, N. Yamazaki, D. Ogata, R. Johnson, B. C. Park, S. Jung, G. Madonna, J. Hochherz, Y. Umeda, Y. Nakamura, C. Gebhardt, L. Festino, M. Capone, P. A. Ascierto, D. B. Johnson, S. N. Lo, G. V. Long, A. M. Menzies, K. Namikawa, M. Mandala, J. Guo, P. Lorigan, Y. G. Najjar, A. Haydon, P. Quaglino, G. M. Boland, R. J. Sullivan, A. J. S. Furness, R. Plummer, and K. T. Flaherty. "Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: A multicenter, retrospective cohort study." EClinicalMedicine 65, no. 102290 (Nov 2023): 102290. https://dx.doi.org/10.1016/j.eclinm.2023.102290.

Simpson, R. C., E. R. Shanahan, R. A. Scolyer, and G. V. Long. "Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors." Nat Rev Clin Oncol 20, no. 10 (Oct 2023): 697–715. https://dx.doi.org/10.1038/s41571-023-00803-9.

Conway, J. W., J. Braden, S. N. Lo, R. A. Scolyer, M. S. Carlino, A. M. Menzies, G. V. Long, and I. P. da Silva. "VEGF inhibitors improve survival outcomes in patients with liver metastases across cancer types – a meta-analysis." Cancers (Basel) 15, no. 20 (Oct 2023): 5012. https://dx.doi.org/10.3390/cancers15205012.

Gide, T. N., E. C. Paver, Z. Yaseen, N. Maher, N. Adegoke, A. M. Menzies, I. P. da Silva, J. S. Wilmott, G. V. Long, and R. A. Scolyer. "LAG-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-LAG-3 plus anti-PD-1-based immunotherapies." Oncoimmunology 12, no. 1 (Oct 2023): 2261248. https://dx.doi.org/10.1080/2162402X.2023.2261248.

Adegoke, N. A., T. N. Gide, Y. Mao, C. Quek, E. Patrick, M. S. Carlino, S. N. Lo, A. M. Menzies, I. P. da Silva, I. A. Vergara, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies." J Immunother Cancer 11, no. 10 (Oct 2023): e007144. https://dx.doi.org/10.1136/jitc-2023-007144.

Shteinman, E. R., I. A. Vergara, R. V. Rawson, S. N. Lo, N. Maeda, K. Koyama, I. P. da Silva, G. V. Long, R. A. Scolyer, J. S. Wilmott, and A. M. Menzies. "Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma." Pathology 55, no. 5 (Aug 2023): 629–36. https://dx.doi.org/10.1016/j.pathol.2023.03.007.

Lee, H., A. L. Ferguson, C. Quek, I. A. Vergara, I. P. da Silva, R. Allen, T. N. Gide, J. W. Conway, L. T. Koufariotis, N. K. Hayward, N. Waddell, M. S. Carlino, A. M. Menzies, R. P. M. Saw, E. Shklovskaya, H. Rizos, S. Lo, R. A. Scolyer, G. V. Long, U. Palendira, and J. S. Wilmott. "Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy." Clin Cancer Res 29, no. 13 (Jul 2023): 2513–24. https://dx.doi.org/10.1158/1078-0432.CCR-22-2657.

Versluis, J. M., A. M. Menzies, K. Sikorska, E. A. Rozeman, R. P. M. Saw, W. J. van Houdt, H. Eriksson, W. M. C. Klop, S. Ch'ng, J. V. van Thienen, H. Mallo, M. Gonzalez, A. Torres Acosta, L. G. Grijpink-Ongering, A. van der Wal, A. Bruining, B. A. van de Wiel, R. A. Scolyer, J. B. A. G. Haanen, T. N. Schumacher, A. C. J. van Akkooi, G. V. Long, and C. U. Blank. "Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials." Ann Oncol 34, no. 4 (Apr 2023): 420–30. https://dx.doi.org/10.1016/j.annonc.2023.01.004.

Mao, Y., T. N. Gide, N. A. Adegoke, C. Quek, N. Maher, A. Potter, E. Patrick, R. P. M. Saw, J. F. Thompson, A. J. Spillane, K. F. Shannon, M. S. Carlino, S. N. Lo, A. M. Menzies, I. P. da Silva, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach." J Transl Med 21, no. 1 (Apr 2023): 257. https://dx.doi.org/10.1186/s12967-023-04092-9.

Wilmott, J. S., H. Tawbi, J. A. Engh, N. M. Amankulor, B. Shivalingam, H. Banerjee, I. A. Vergara, H. Lee, P. A. Johansson, P. M. Ferguson, P. Saiag, C. Robert, J. J. Grob, L. H. Butterfield, R. A. Scolyer, J. M. Kirkwood, G. V. Long, and M. A. Davies. "Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases." Clin Cancer Res 29, no. 3 (Feb 2023): 521–31. https://dx.doi.org/10.1158/1078-0432.CCR-22-2581.

2022

Rawson, R. V., E. R. Shteinman, S. Ansar, I. A. Vergara, J. F. Thompson, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Diagnostic utility of PRAME, p53, and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars, and other histological mimics." Pathology 54, no. 7 (Dec 2022): 863–73. https://dx.doi.org/10.1016/j.pathol.2022.05.012.

Newell, F., P. A. Johansson, J. S. Wilmott, K. Nones, V. Lakis, A. L. Pritchard, S. N. Lo, R. V. Rawson, S. H. Kazakoff, A. J. Colebatch, L. T. Koufariotis, P. M. Ferguson, S. Wood, C. Leonard, M. H. Law, K. M. Brooks, N. Broit, J. M. Palmer, K. L. Couts, I. A. Vergara, G. V. Long, A. P. Barbour, O. E. Nieweg, B. Shivalingam, W. A. Robinson, J. R. Stretch, A. J. Spillane, R. P. M. Saw, K. F. Shannon, J. F. Thompson, G. J. Mann, J. V. Pearson, R. A. Scolyer, N. Waddell, and N. K. Hayward. "Comparative genomics provides etiologic and biological insight into melanoma subtypes." Cancer Discov 12, no. 12 (Dec 2022): 2856–79. https://dx.doi.org/10.1158/2159-8290.CD-22-0603.

Simpson, R. C., E. R. Shanahan, M. Batten, I. L. M. Reijers, M. Read, I. P. da Silva, J. M. Versluis, R. Ribeiro, A. S. Angelatos, J. Tan, C. Adhikari, A. M. Menzies, R. P. M. Saw, M. Gonzalez, K. F. Shannon, A. J. Spillane, R. Velickovic, A. J. Lazar, A. V. Damania, A. K. Mishra, M. Chelvanambi, A. Banerjee, N. J. Ajami, J. A. Wargo, L. Macia, A. J. Holmes, J. S. Wilmott, C. U. Blank, R. A. Scolyer, and G. V. Long. "Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome." Nat Med 28, no. 11 (Nov 2022): 2344–52. https://dx.doi.org/10.1038/s41591-022-01965-2.

Conway, J. W., J. Braden, J. S. Wilmott, R. A. Scolyer, G. V. Long, and I. P. da Silva. "The effect of organ-specific tumor microenvironments on response patterns to immunotherapy." Front Immunol 13 (Nov 2022): 1030147. https://dx.doi.org/10.3389/fimmu.2022.1030147.

Nahar, K. J., F. Marsh-Wakefield, R. V. Rawson, T. N. Gide, A. L. Ferguson, R. Allen, C. Quek, I. P. da Silva, S. Tattersal, C. J. Kiely, N. Sandanayake, M. S. Carlino, G. McCaughan, J. S. Wilmott, R. A. Scolyer, G. V. Long, A. M. Menzies, and U. Palendira. "Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis." JCI Insight 7, no. 21 (Nov 2022): e157839. https://dx.doi.org/10.1172/jci.insight.157839.

Shteinman, E. R., J. S. Wilmott, I. P. da Silva, G. V. Long, R. A. Scolyer, and I. A. Vergara. "Causes, consequences, and clinical significance of aneuploidy across melanoma subtypes." Front Oncol 12 (Oct 2022): 988691. https://dx.doi.org/10.3389/fonc.2022.988691.

Conway, J. W., R. V. Rawson, S. Lo, T. Ahmed, I. A. Vergara, T. N. Gide, G. H. Attrill, M. S. Carlino, R. P. M. Saw, J. F. Thompson, A. J. Spillane, K. F. Shannon, B. Shivalingam, A. M. Menzies, J. S. Wilmott, G. V. Long, R. A. Scolyer, and I. P. da Silva. "Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites." J Immunother Cancer 10, no. 9 (Sep 2022): e004884. https://dx.doi.org/10.1136/jitc-2022-004884.

Attrill, G. H., H. Lee, A. T. Tasker, N. A. Adegoke, A. L. Ferguson, I. P. da Silva, R. P. M. Saw, J. F. Thompson, U. Palendira, G. V. Long, P. M. Ferguson, R. A. Scolyer, and J. S. Wilmott. "Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome." Front Immunol 13 (Aug 2022): 979993. https://dx.doi.org/10.3389/fimmu.2022.979993.

Colebatch, A. J., E. C. Paver, I. A. Vergara, J. F. Thompson, G. V. Long, J. S. Wilmott, and R. A. Scolyer. "Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma." Pathology 54, no. 5 (Aug 2022): 533–40. https://dx.doi.org/10.1016/j.pathol.2021.12.289.

Colebatch, A. J., C. Adhikari, R. J. Diefenbach, R. V. Rawson, P. M. Ferguson, H. Rizos, G. V. Long, S. W. McCarthy, J. F. Thompson, J. S. Wilmott, and R. A. Scolyer. "Comprehensive clinical, histopathologic, and molecular analysis and long-term follow-up of patients with nodal blue nevi." Am J Surg Pathol 46, no. 8 (Aug 2022): 1048–59. https://dx.doi.org/10.1097/PAS.0000000000001902.

Reijers, I. L. M., A. M. Menzies, A. C. J. van Akkooi, J. M. Versluis, N. M. J. van den Heuvel, R. P. M. Saw, T. E. Pennington, E. Kapiteijn, A. A. M. van der Veldt, K. P. M. Suijkerbuijk, G. A. P. Hospers, E. A. Rozeman, W. M. C. Klop, W. J. van Houdt, K. Sikorska, J. A. van der Hage, D. J. Grunhagen, M. W. Wouters, A. J. Witkamp, C. L. Zuur, J. M. Lijnsvelt, A. Torres Acosta, L. G. Grijpink-Ongering, M. Gonzalez, K. Jozwiak, C. Bierman, K. F. Shannon, S. Ch'ng, A. J. Colebatch, A. J. Spillane, J. B. A G. Haanen, R. V. Rawson, B. A. van de Wiel, L. V. van de Poll-Franse, R. A. Scolyer, A. H. Boekhout, G. V. Long, and C. U. Blank. "Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial." Nat Med 28, no. 6 (Jun 2022): 1178–88. https://dx.doi.org/10.1038/s41591-022-01851-x.

Attrill, G. H., C. N. Owen, T. Ahmed, I. A. Vergara, A. J. Colebatch, J. W. Conway, K. J. Nahar, J. F. Thompson, I. P. da Silva, M. S. Carlino, A. M. Menzies, S. Lo, U. Palendira, R. A. Scolyer, G. V. Long, and J. S. Wilmott. "Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy." J Immunother Cancer 10, no. 6 (Jun 2022): e004771. https://dx.doi.org/10.1136/jitc-2022-004771.

Yaseen, Z., T. N. Gide, J. W. Conway, A. J. Potter, C. Quek, A. M. Hong, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Validation of an accurate automated multiplex immunofluorescence method for immuno-profiling melanoma." Front Mol Biosci 9 (May 2022): 810858. https://dx.doi.org/10.3389/fmolb.2022.810858.

da Silva, I. P., T. Ahmed, J. L. McQuade, C. A. Nebhan, J. J. Park, J. M. Versluis, P. Serra-Bellver, Y. Khan, T. Slattery, H. K. Oberoi, S. Ugurel, L. E. Haydu, R. Herbst, J. Utikal, C. Pfohler, P. Terheyden, M. Weichenthal, R. Gutzmer, P. Mohr, R. Rai, J. L. Smith, R. A. Scolyer, A. M. Arance, L. Pickering, J. Larkin, P. Lorigan, C. U. Blank, D. Schadendorf, M. A. Davies, M. S. Carlino, D. B. Johnson, G. V. Long, S. N. Lo, and A. M. Menzies. "Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma." J Clin Oncol 40, no. 10 (Apr 2022): 1068–80. https://dx.doi.org/10.1200/JCO.21.01701.

Newell, F., I. P. da Silva, P. A. Johansson, A. M. Menzies, J. S. Wilmott, V. Addala, M. S. Carlino, H. Rizos, K. Nones, J. J. Edwards, V. Lakis, S. H. Kazakoff, P. Mukhopadhyay, P. M. Ferguson, C. Leonard, L. T. Koufariotis, S. Wood, C. U. Blank, J. F. Thompson, A. J. Spillane, R. P. M. Saw, K. F. Shannon, J. V. Pearson, G. J. Mann, N. K. Hayward, R. A. Scolyer, N. Waddell, and G. V. Long. "Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance." Cancer Cell 40, no. 1 (Jan 2022): 88–102. https://dx.doi.org/10.1016/j.ccell.2021.11.012.

Vergara, I. A., J. S. Wilmott, G. V. Long, and R. A. Scolyer. "Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape." Exp Dermatol 31, no. 1 (Jan 2022): 13–30. https://dx.doi.org/10.1111/exd.14287.

2021

Quek, C., X. Bai, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "High-dimensional single-cell transcriptomics in melanoma and cancer immunotherapy." Genes (Basel) 12, no. 10 (Oct 2021): 1629. https://dx.doi.org/10.3390/genes12101629.

Haas, L., A. Elewaut, C. L. Gerard, C. Umkehrer, L. Leiendecker, M. Pedersen, I. Krecioch, D. Hoffmann, M. Novatchkova, M. Kuttke, T. Neumann, I. P. da Silva, H. Witthock, M. A. Cuendet, S. Carotta, K. J. Harrington, J. Zuber, R. A. Scolyer, G. V. Long, J. S. Wilmott, O. Michielin, S. Vanharanta, T. Wiesner, and A. C. Obenauf. "Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma." Nat Cancer 2, no. 7 (Jul 2021): 693–708. https://dx.doi.org/10.1038/s43018-021-00221-9.

Gide, T. N., I. P. da Silva, C. Quek, P. M. Ferguson, M. Batten, P. Shang, T. Ahmed, A. M. Menzies, M. S. Carlino, R. P. M. Saw, J. F. Thompson, R. A. Scolyer, G. V. Long, and J. S. Wilmott. "Clinical and molecular heterogeneity in patients with innate resistance to anti-PD-1+/– anti-CTLA-4 immunotherapy in metastatic melanoma reveals distinct therapeutic targets." Cancers (Basel) 13, no. 13 (Jun 2021): 3186. https://dx.doi.org/10.3390/cancers13133186.

Wu, S. Z., D. L. Roden, G. Al-Eryani, N. Bartonicek, K. Harvey, A. S. Cazet, C. L. Chan, S. Junankar, M. N. Hui, E. A. Millar, J. Beretov, L. Horvath, A. M. Joshua, P. Stricker, J. S. Wilmott, C. Quek, G. V. Long, R. A. Scolyer, B. Z. Yeung, D. Segara, C. Mak, S. Warrier, J. E. Powell, S. O'Toole, E. Lim, and A. Swarbrick. "Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis." Genome Med 13, no. 1 (May 2021): 81. https://dx.doi.org/10.1186/s13073-021-00885-z.

Attrill, G. H., P. M. Ferguson, U. Palendira, G. V. Long, J. S. Wilmott, and R. A. Scolyer. "The tumour immune landscape and its implications in cutaneous melanoma." Pigment Cell Melanoma Res 34, no. 3 (May 2021): 529–49. https://dx.doi.org/10.1111/pcmr.12926.

Lee, H., I. P. da Silva, U. Palendira, R. A. Scolyer, G. V. Long, and J. S. Wilmott. "Targeting NK cells to enhance melanoma response to immunotherapies." Cancers (Basel) 13, no. 6 (Mar 2021): 1363. https://dx.doi.org/10.3390/cancers13061363.

Rozeman, E. A., E. P. Hoefsmit, I. L. M. Reijers, R. P. M. Saw, J. M. Versluis, O. Krijgsman, P. Dimitriadis, K. Sikorska, B. A. van de Wiel, H. Eriksson, M. Gonzalez, A. Torres Acosta, L. G. Grijpink-Ongering, K. Shannon, J. B. A. G. Haanen, J. Stretch, S. Ch'ng, O. E. Nieweg, H. A. Mallo, S. Adriaansz, R. M. Kerkhoven, S. Cornelissen, A. Broeks, W. M. C. Klop, C. L. Zuur, W. J. van Houdt, D. S. Peeper, A. J. Spillane, A. C. J. van Akkooi, R. A. Scolyer, T. N. M. Schumacher, A. M. Menzies, G. V. Long, and C. U. Blank. "Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma." Nat Med 27, no. 2 (Feb 2021): 256–63. https://dx.doi.org/10.1038/s41591-020-01211-7.

Simpson, R. C., E. Shanahan, R. A. Scolyer, and G. V. Long. "Targeting the microbiome to overcome resistance." Cancer Cell 39, no. 2 (Feb 2021): 151–53. https://dx.doi.org/10.1016/j.ccell.2021.01.016.

2020

Hoefsmit, E. P., E. A. Rozeman, T. M. Van, P. Dimitriadis, O. Krijgsman, J. W. Conway, I. P. da Silva, J. E. van der Wal, S. L. C. Ketelaars, K. Bresser, A. Broeks, R. M. Kerkhoven, J. W. Reeves, S. Warren, P. Kvistborg, R. A. Scolyer, E. W. Kapiteijn, D. S. Peeper, G. V. Long, T. N. M. Schumacher, and C. U. Blank. "Comprehensive analysis of cutaneous and uveal melanoma liver metastases." J Immunother Cancer 8, no. 2 (Dec 2020): e001501. https://dx.doi.org/10.1136/jitc-2020-001501.

Edwards, J., P. M. Ferguson, S. N. Lo, I. P. da Silva, A. J. Colebatch, H. Lee, R. P. M. Saw, J. F. Thompson, A. M. Menzies, G. V. Long, F. Newell, J. V. Pearson, N. Waddell, N. K. Hayward, P. A. Johansson, G. J. Mann, R. A. Scolyer, U. Palendira, and J. S. Wilmott. "Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas." Cancer Immunol Res 8, no. 11 (Nov 2020): 1346–53. https://dx.doi.org/10.1158/2326-6066.CIR-19-0835.

Gide, T. N., I. P. da Silva, C. Quek, T. Ahmed, A. M. Menzies, M. S. Carlino, R. P. M. Saw, J. F. Thompson, M. Batten, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients." Oncoimmunology 9, no. 1 (Oct 2020): 1659093. https://dx.doi.org/10.1080/2162402X.2019.1659093.

Bailey, M. H., W. U. Meyerson, L. J. Dursi, L. B. Wang, G. Dong, W. W. Liang, A. Weerasinghe, S. Li, Y. Li, S. Kelso, The MC3 Working Group, PCAWG Novel Somatic Mutation Calling Methods Working Group, G. Saksena, K. Ellrott, M. C. Wendl, D. A. Wheeler, G. Getz, J. T. Simpson, M. B. Gerstein, L. Ding, and PCWAG Consortium. "Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples." Nat Commun 11, no. 1 (Sep 2020): 4748. https://dx.doi.org/10.1038/s41467-020-18151-y.

Li, C. H., S. D. Prokopec, R. X. Sun, F. Yousif, N. Schmitz, PCAWG Tumour Subtypes and Clinical Translation, P. C. Boutros, and PCAWG Consortium. "Sex differences in oncogenic mutational processes." Nat Commun 11, no. 1 (Aug 2020): 4330. https://dx.doi.org/10.1038/s41467-020-17359-2.

McKelvey, K. J., A. L. Hudson, R. Prasanna Kumar, J. S. Wilmott, G. H. Attrill, G. V. Long, R. A. Scolyer, S. J. Clarke, H. R. Wheeler, C. I. Diakos, and V. M. Howell. "Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model." PLoS One 15, no. 4 (Apr 2020): e0226444. https://dx.doi.org/10.1371/journal.pone.0226444.

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. "Pan-cancer analysis of whole genomes." Nature 578, no. 7793 (Feb 2020): 82–93. https://dx.doi.org/10.1038/s41586-020-1969-6.

da Silva, I. P., S. Lo, C. Quek, M. Gonzalez, M. S. Carlino, G. V. Long, and A. M. Menzies. "Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy." Cancer 126, no. 1 (Jan 2020): 86–97. https://dx.doi.org/10.1002/cncr.32522.

House, I. G., P. Savas, J. Lai, A. X. Y. Chen, A. J. Oliver, Z. L. Teo, K. L. Todd, M. A. Henderson, L. Giuffrida, E. V. Petley, K. Sek, S. Mardiana, T. N. Gide, C. Quek, R. A. Scolyer, G. V. Long, J. S. Wilmott, S. Loi, P. K. Darcy, and P. A. Beavis. "Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade." Clin Cancer Res 26, no. 2 (Jan 2020): 487–504. https://dx.doi.org/10.1158/1078-0432.CCR-19-1868.

2019

Lee, H., C. Quek, I. P. da Silva, A. Tasker, M. Batten, H. Rizos, S. Y. Lim, T. Nur Gide, P. Shang, G. H. Attrill, J. Madore, J. Edwards, M. S. Carlino, A. Guminski, R. P. M. Saw, J. F. Thompson, P. M. Ferguson, U. Palendira, A. M. Menzies, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients." Oncoimmunology 8, no. 2 (Oct 2019): e1537581. https://dx.doi.org/10.1080/2162402X.2018.1537581.

Colebatch, A. J., P. Ferguson, F. Newell, S. H. Kazakoff, T. Witkowski, A. Dobrovic, P. A. Johansson, R. P. M. Saw, J. R. Stretch, G. A. McArthur, G. V. Long, J. F. Thompson, J. V. Pearson, G. J. Mann, N. K. Hayward, N. Waddell, R. A. Scolyer, and J. S. Wilmott. "Molecular genomic profiling of melanocytic nevi." J Invest Dermatol 139, no. 8 (Aug 2019): 1762–68. https://dx.doi.org/10.1016/j.jid.2018.12.033.

Rozeman, E. A., A. M. Menzies, A. C. J. van Akkooi, C. Adhikari, C. Bierman, B. A. van de Wiel, R. A. Scolyer, O. Krijgsman, K. Sikorska, H. Eriksson, A. Broeks, J. V. van Thienen, A. D. Guminski, A. T. Acosta, S. Ter Meulen, A. M. Koenen, L. J. W. Bosch, K. Shannon, L. M. Pronk, M. Gonzalez, S. Ch'ng, L. G. Grijpink-Ongering, J. Stretch, S. Heijmink, H. van Tinteren, J. B. A. G. Haanen, O. E. Nieweg, W. M. C. Klop, C. L. Zuur, R. P. M. Saw, W. J. van Houdt, D. S. Peeper, A. J. Spillane, J. Hansson, T. N. Schumacher, G. V. Long, and C. U. Blank. "Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial." Lancet Oncol 20, no. 7 (Jul 2019): 948–60. https://dx.doi.org/10.1016/S1470-2045(19)30151-2.

da Silva, I. P., I. C. Glitza, L. E. Haydu, R. Johnpulle, P. D. Banks, G. D. Grass, S. M. A. Goldinger, J. L. Smith, A. S. Everett, P. Koelblinger, R. Roberts-Thomson, M. Millward, V. G. Atkinson, A. Guminski, R. Kapoor, R. M. Conry, M. S. Carlino, W. Wang, M. J. Shackleton, Z. Eroglu, S. N. Lo, A. M. Hong, G. V. Long, D. B. Johnson, and A. M. Menzies. "Incidence, features, and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies." Pigment Cell Melanoma Res 32, no. 4 (Jul 2019): 553–63. https://dx.doi.org/10.1111/pcmr.12775.

Edwards, J., A. Tasker, I. P. da Silva, C. Quek, M. Batten, A. Ferguson, R. Allen, B. Allanson, R. P. M. Saw, J. F. Thompson, A. M. Menzies, U. Palendira, J. S. Wilmott, G. V. Long, and R. A. Scolyer. "Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naive melanoma patients: Implications for clinical trials." Clin Cancer Res 25, no. 11 (Jun 2019): 3247–58. https://dx.doi.org/10.1158/1078-0432.CCR-18-4011.

Gide, T. N., B. M. Allanson, A. M. Menzies, P. M. Ferguson, J. Madore, R. P. M. Saw, J. F. Thompson, G. V. Long, J. S. Wilmott, and R. A. Scolyer. "Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment." Histopathology 74, no. 6 (May 2019): 817–28. https://dx.doi.org/10.1111/his.13814.

Wilmott, J. S., P. A. Johansson, F. Newell, N. Waddell, P. Ferguson, C. Quek, A. M. Patch, K. Nones, P. Shang, A. L. Pritchard, S. Kazakoff, O. Holmes, C. Leonard, S. Wood, Q. Xu, R. P. M. Saw, A. J. Spillane, J. R. Stretch, K. F. Shannon, R. F. Kefford, A. M. Menzies, G. V. Long, J. F. Thompson, J. V. Pearson, G. J. Mann, N. K. Hayward, and R. A. Scolyer. "Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility." Int J Cancer 144, no. 5 (Mar 2019): 1049–60. https://dx.doi.org/10.1002/ijc.31791.

Lim, S. Y., J. H. Lee, T. N. Gide, A. M. Menzies, A. Guminski, M. S. Carlino, E. J. Breen, J. Y. H. Yang, S. Ghazanfar, R. F. Kefford, R. A. Scolyer, G. V. Long, and H. Rizos. "Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy." Clin Cancer Res 25, no. 5 (Mar 2019): 1557–63. https://dx.doi.org/10.1158/1078-0432.CCR-18-2795.

Gide, T. N., C. Quek, A. M. Menzies, A. T. Tasker, P. Shang, J. Holst, J. Madore, S. Y. Lim, R. Velickovic, M. Wongchenko, Y. Yan, S. N. Lo, M. S. Carlino, A. Guminski, R. P. M. Saw, A. Pang, H. M. McGuire, U. Palendira, J. F. Thompson, H. Rizos, I. P. da Silva, M. Batten, R. A. Scolyer, G. V. Long, and J. S. Wilmott. "Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy." Cancer Cell 35, no. 2 (Feb 2019): 238–55. https://dx.doi.org/10.1016/j.ccell.2019.01.003.

da Silva, I. P., K. Y. X. Wang, J. S. Wilmott, J. Holst, M. S. Carlino, J. J. Park, C. Quek, M. Wongchenko, Y. Yan, G. Mann, D. B. Johnson, J. L. McQuade, R. Rai, R. F. Kefford, H. Rizos, R. A. Scolyer, J. Y. H. Yang, G. V. Long, and A. M. Menzies. "Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma." Clin Cancer Res 25, no. 4 (Feb 2019): 1272–79. https://dx.doi.org/10.1158/1078-0432.CCR-18-1680.

Quek, C., R. V. Rawson, P. M. Ferguson, P. Shang, I. P. da Silva, R. P. M. Saw, K. Shannon, J. F. Thompson, N. K. Hayward, G. V. Long, G. J. Mann, R. A. Scolyer, and J. S. Wilmott. "Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas." Oncotarget 10, no. 9 (Jan 2019): 930–41. https://dx.doi.org/10.18632/oncotarget.26584.

2018

Korkut, A., S. Zaidi, R. S. Kanchi, S. Rao, N. R. Gough, A. Schultz, X. Li, P. L. Lorenzi, A. C. Berger, G. Robertson, L. N. Kwong, M. Datto, J. Roszik, S. Ling, V. Ravikumar, G. Manyam, A. Rao, S. Shelley, Y. Liu, Z. Ju, D. Hansel, G. de Velasco, A. Pennathur, J. B. Andersen, C. J. O'Rourke, K. Ohshiro, W. Jogunoori, B. N. Nguyen, S. Li, H. U. Osmanbeyoglu, J. A. Ajani, S. A. Mani, A. Houseman, M. Wiznerowicz, J. Chen, S. Gu, W. Ma, J. Zhang, P. Tong, A. D. Cherniack, C. Deng, L. Resar, Cancer Genome Atlas Research Network, J. N. Weinstein, L. Mishra, and R. Akbani. "A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-beta superfamily." Cell Syst 7, no. 4 (Oct 2018): 422–37. https://dx.doi.org/10.1016/j.cels.2018.08.010.

Edwards, J., J. S. Wilmott, J. Madore, T. N. Gide, C. Quek, A. Tasker, A. Ferguson, J. Chen, R. Hewavisenti, P. Hersey, T. Gebhardt, W. Weninger, W. J. Britton, R. P. M. Saw, J. F. Thompson, A. M. Menzies, G. V. Long, R. A. Scolyer, and U. Palendira. "CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment." Clin Cancer Res 24, no. 13 (Jul 2018): 3036–45. https://dx.doi.org/10.1158/1078-0432.CCR-17-2257.

Long, G. V., V. Atkinson, S. Lo, S. Sandhu, A. D. Guminski, M. P. Brown, J. S. Wilmott, J. Edwards, M. Gonzalez, R. A. Scolyer, A. M. Menzies, and G. A. McArthur. "Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study." Lancet Oncol 19, no. 5 (May 2018): 672–81. https://dx.doi.org/10.1016/S1470-2045(18)30139-6.

Bailey, M. H., C. Tokheim, E. Porta-Pardo, S. Sengupta, D. Bertrand, A. Weerasinghe, A. Colaprico, M. C. Wendl, J. Kim, B. Reardon, P. K. Ng, K. J. Jeong, S. Cao, Z. Wang, J. Gao, Q. Gao, F. Wang, E. M. Liu, L. Mularoni, C. Rubio-Perez, N. Nagarajan, I. Cortes-Ciriano, D. C. Zhou, W. W. Liang, J. M. Hess, V. D. Yellapantula, D. Tamborero, A. Gonzalez-Perez, C. Suphavilai, J. Y. Ko, E. Khurana, P. J. Park, E. M. van Allen, H. Liang, The MC3 Working Group, Cancer Genome Atlas Research Network, M. S. Lawrence, A. Godzik, N. Lopez-Bigas, J. Stuart, D. Wheeler, G. Getz, K. Chen, A. J. Lazar, G. B. Mills, R. Karchin, and L. Ding. "Comprehensive characterization of cancer driver genes and mutations." Cell 173, no. 2 (Apr 2018): 371–85. https://dx.doi.org/10.1016/j.cell.2018.02.060.

Ding, L., M. H. Bailey, E. Porta-Pardo, V. Thorsson, A. Colaprico, D. Bertrand, D. L. Gibbs, A. Weerasinghe, K. L. Huang, C. Tokheim, I. Cortes-Ciriano, R. Jayasinghe, F. Chen, L. Yu, S. Sun, C. Olsen, J. Kim, A. M. Taylor, A. D. Cherniack, R. Akbani, C. Suphavilai, N. Nagarajan, J. M. Stuart, G. B. Mills, M. A. Wyczalkowski, B. G. Vincent, C. M. Hutter, J. C. Zenklusen, K. A. Hoadley, M. C. Wendl, L. Shmulevich, A. J. Lazar, D. A. Wheeler, G. Getz, and Cancer Genome Atlas Research Network. "Perspective on oncogenic processes at the end of the beginning of cancer genomics." Cell 173, no. 2 (Apr 2018): 305–20. https://dx.doi.org/10.1016/j.cell.2018.03.033.

Ge, Z., J. S. Leighton, Y. Wang, X. Peng, Z. Chen, H. Chen, Y. Sun, F. Yao, J. Li, H. Zhang, J. Liu, C. D. Shriver, H. Hu, Cancer Genome Atlas Research Network, H. Piwnica-Worms, L. Ma, and H. Liang. "Integrated genomic analysis of the ubiquitin pathway across cancer types." Cell Rep 23, no. 1 (Apr 2018): 213–26. https://dx.doi.org/10.1016/j.celrep.2018.03.047.

Liu, J., T. Lichtenberg, K. A. Hoadley, L. M. Poisson, A. J. Lazar, A. D. Cherniack, A. J. Kovatich, C. C. Benz, D. A. Levine, A. V. Lee, L. Omberg, D. M. Wolf, C. D. Shriver, V. Thorsson, Cancer Genome Atlas Research Network, and H. Hu. "An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics." Cell 173, no. 2 (Apr 2018): 400–16. https://dx.doi.org/10.1016/j.cell.2018.02.052.

Sanchez-Vega, F., M. Mina, J. Armenia, W. K. Chatila, A. Luna, K. C. La, S. Dimitriadoy, D. L. Liu, H. S. Kantheti, S. Saghafinia, D. Chakravarty, F. Daian, Q. Gao, M. H. Bailey, W. W. Liang, S. M. Foltz, I. Shmulevich, L. Ding, Z. Heins, A. Ochoa, B. Gross, J. Gao, H. Zhang, R. Kundra, C. Kandoth, I. Bahceci, L. Dervishi, U. Dogrusoz, W. Zhou, H. Shen, P. W. Laird, G. P. Way, C. S. Greene, H. Liang, Y. Xiao, C. Wang, A. Iavarone, A. H. Berger, T. G. Bivona, A. J. Lazar, G. D. Hammer, T. Giordano, L. N. Kwong, G. McArthur, C. Huang, A. D. Tward, M. J. Frederick, F. McCormick, M. Meyerson, Cancer Genome Atlas Research Network, E. M. Van Allen, A. D. Cherniack, G. Ciriello, C. Sander, and N. Schultz. "Oncogenic signaling pathways in the cancer genome atlas." Cell 173, no. 2 (Apr 2018): 321–37. https://dx.doi.org/10.1016/j.cell.2018.03.035.

Thorsson, V., D. L. Gibbs, S. D. Brown, D. Wolf, D. S. Bortone, T. H. Ou Yang, E. Porta-Pardo, G. F. Gao, C. L. Plaisier, J. A. Eddy, E. Ziv, A. C. Culhane, E. O. Paull, I. K. A. Sivakumar, A. J. Gentles, R. Malhotra, F. Farshidfar, A. Colaprico, J. S. Parker, L. E. Mose, N. S. Vo, J. Liu, Y. Liu, J. Rader, V. Dhankani, S. M. Reynolds, R. Bowlby, A. Califano, A. D. Cherniack, D. Anastassiou, D. Bedognetti, Y. Mokrab, A. M. Newman, A. Rao, K. Chen, A. Krasnitz, H. Hu, T. M. Malta, H. Noushmehr, C. S. Pedamallu, S. Bullman, A. I. Ojesina, A. Lamb, W. Zhou, H. Shen, T. K. Choueiri, J. N. Weinstein, J. Guinney, J. Saltz, R. A. Holt, C. S. Rabkin, Cancer Genome Atlas Research Network, A. J. Lazar, J. S. Serody, E. G. Demicco, M. L. Disis, B. G. Vincent, and I. Shmulevich. "The immune landscape of cancer." Immunity 48, no. 4 (Apr 2018): 812–30. https://dx.doi.org/10.1016/j.immuni.2018.03.023.

Gide, T. N., J. S. Wilmott, R. A. Scolyer, and G. V. Long. "Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma." Clin Cancer Res 24, no. 6 (Mar 2018): 1260–70. https://dx.doi.org/10.1158/1078-0432.CCR-17-2267.

Pre-2018

Kakavand, H., L. A. Jackett, A. M. Menzies, T. N. Gide, M. S. Carlino, R. P. M. Saw, J. F. Thompson, J. S. Wilmott, G. V. Long, and R. A. Scolyer. "Negative immune checkpoint regulation by vista: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients." Mod Pathol 30, no. 12 (Dec 2017): 1666–76. https://dx.doi.org/10.1038/modpathol.2017.89.

Hayward, N. K., J. S. Wilmott, N. Waddell, P. A. Johansson, M. A. Field, K. Nones, A. M. Patch, H. Kakavand, L. B. Alexandrov, H. Burke, V. Jakrot, S. Kazakoff, O. Holmes, C. Leonard, R. Sabarinathan, L. Mularoni, S. Wood, Q. Xu, N. Waddell, V. Tembe, G. M. Pupo, R. De Paoli-Iseppi, R. E. Vilain, P. Shang, L. M. S. Lau, R. A. Dagg, S. J. Schramm, A. Pritchard, K. Dutton-Regester, F. Newell, A. Fitzgerald, C. A. Shang, S. M. Grimmond, H. A. Pickett, J. Y. Yang, J. R. Stretch, A. Behren, R. F. Kefford, P. Hersey, G. V. Long, J. Cebon, M. Shackleton, A. J. Spillane, R. P. M. Saw, N. Lopez-Bigas, J. V. Pearson, J. F. Thompson, R. A. Scolyer, and G. J. Mann. "Whole-genome landscapes of major melanoma subtypes." Nature 545, no. 7653 (May 2017): 175–80. https://dx.doi.org/10.1038/nature22071.

Cancer Genome Atlas Network. "Genomic classification of cutaneous melanoma." Cell 161, no. 7 (Jun 2015): 1681–96. https://dx.doi.org/10.1016/j.cell.2015.05.044.